Status:

ACTIVE_NOT_RECRUITING

Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Estrogen Receptor Positive

HER2/Neu Negative

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This phase II trial studies how well radiation therapy before surgery works in treating patients with hormone receptor positive, HER2 negative breast cancer. Radiation therapy uses high energy x-rays ...

Detailed Description

PRIMARY OBJECTIVES: I. To evaluate the change in percent tumor-infiltrating lymphocytes (TIL) as a continuous variable before and after preoperative boost radiotherapy (RT) in hormone receptor (HR)+/...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Inclusion:
  • Age \>/=18 years at time of study entry
  • Histologically confirmed HR+/HER2- (according to American Society of Clinical Oncology/College of American Pathologists guidelines) invasive carcinoma of the breast
  • Presence of a clip in the primary breast cancer
  • Biopsy-amenable residual disease in the breast measuring \>/= 1cm in at least one dimension on ultrasound cm in at least one dimension on ultrasound
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Signed written informed consent
  • Planned for multidisciplinary evaluation by a Breast Surgical Oncologist and Breast Radiation Oncologist. For patients undergoing mastectomy and desirous of reconstruction or those undergoing breast conservation in whom oncoplastic local tissue rearrangement or reduction mammoplasty is being considered, this multidisciplinary evaluation will also include a plastic surgeon.
  • Exclusion:
  • Women who are pregnant or breast-feeding
  • Contraindication to receive radiotherapy

Exclusion

    Key Trial Info

    Start Date :

    November 16 2017

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    October 31 2027

    Estimated Enrollment :

    25 Patients enrolled

    Trial Details

    Trial ID

    NCT03359954

    Start Date

    November 16 2017

    End Date

    October 31 2027

    Last Update

    September 29 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    M D Anderson Cancer Center

    Houston, Texas, United States, 77030